MYC and glioblastoma: For instance, USP13 deubiquitinated c-MYC in glioblastoma and lung squamous cell carcinoma to promote disease progression [12, 21]; USP13 oncogenically stabilized MCL-1 in ovarian and lung cancer and de-sensitized tumor cells to BH3 mimetic inhibitors [13].